The Motley Fool27d
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
Investopedia2d
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Matthias Balk / picture alliance via Getty Images Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration. The pharmaceutical firm called ...
Business Insider3d
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
Yahoo Finance2d
Bristol-Myers Squibb Company (BMY)
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Morningstar4d
Bristol-Myers Squibb Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...